PolyPeptide Group Dividends and Buybacks

Dividend criteria checks 0/6

PolyPeptide Group does not currently pay a dividend.

Key information

Dividend yield

0.1%

Buyback Yield

Total Shareholder Yield	0.1%
Future Dividend Yield	0.6%
Dividend Growth	n/a
Next dividend pay date	n/a
Ex dividend date	n/a
Dividend per share	CHF 0.300
Payout ratio	0%

Recent dividend and buyback updates

Recent updates

PolyPeptide Group AG's (VTX:PPGN) Intrinsic Value Is Potentially 19% Below Its Share Price

Nov 11

Further Upside For PolyPeptide Group AG (VTX:PPGN) Shares Could Introduce Price Risks After 33% Bounce

Mar 14

PolyPeptide Group AG's (VTX:PPGN) Intrinsic Value Is Potentially 99% Above Its Share Price

Mar 13

PolyPeptide Group AG Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Mar 18

Investors Shouldn't Be Too Comfortable With PolyPeptide Group's (VTX:PPGN) Robust Earnings

Mar 23

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if PPGN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PPGN's dividend payments have been increasing.

Dividend Yield vs Market

PolyPeptide Group Dividend Yield vs Market

How does PPGN dividend yield compare to the market?
Segment	Dividend Yield
Company (PPGN)	0%
Market Bottom 25% (CH)	2.0%
Market Top 25% (CH)	4.4%
Industry Average (Life Sciences)	0.8%
Analyst forecast (PPGN) (up to 3 years)	0.6%

Notable Dividend: Unable to evaluate PPGN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate PPGN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: PPGN is not paying a notable dividend for the Swiss market.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as PPGN has not reported any payouts.

PolyPeptide Group Dividends and Buybacks

Dividend criteria checks 0/6

Key information

Recent dividend and buyback updates

PolyPeptide Group AG Approves Cash Distribution for the Year 2021, Payable on May 02, 2022

PolyPeptide Group AG Proposes Cash Distribution for the Year 2021

Recent updates

PolyPeptide Group AG's (VTX:PPGN) Intrinsic Value Is Potentially 19% Below Its Share Price

Now 22% overvalued after recent price rise

PolyPeptide Group (VTX:PPGN) Is Making Moderate Use Of Debt

Sentiment Still Eluding PolyPeptide Group AG (VTX:PPGN)

Consensus EPS estimates fall by 16%

Consensus EPS estimates fall by 15%

Does PolyPeptide Group (VTX:PPGN) Have A Healthy Balance Sheet?

Consensus EPS estimates fall by 17%, revenue upgraded

Further Upside For PolyPeptide Group AG (VTX:PPGN) Shares Could Introduce Price Risks After 33% Bounce

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

PolyPeptide Group AG's (VTX:PPGN) Intrinsic Value Is Potentially 99% Above Its Share Price

New major risk - Share price stability

PolyPeptide Group AG, Annual General Meeting, Apr 09, 2025

PolyPeptide Group AG to Report First Half, 2025 Results on Aug 12, 2025

First half 2023 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates fall from profit to €1.13 loss

New major risk - Share price stability

Consensus EPS estimates fall by 24%

Consensus EPS estimates fall by 17%

Consensus EPS estimates fall by 16%

PolyPeptide Group AG Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Full year 2022 earnings: EPS and revenues miss analyst expectations

Investor sentiment deteriorates as stock falls 21%

Consensus EPS estimates fall by 19%

PolyPeptide Group AG to Report First Half, 2024 Results on Aug 13, 2024

PolyPeptide Group AG Appoints Peter Wilden as Executive Chairman

Now 21% undervalued after recent price drop

Now 20% undervalued after recent price drop

Consensus forecasts updated

Consensus EPS estimates fall by 13%

Investor sentiment deteriorated over the past week

High number of new and inexperienced directors

Investor sentiment improved over the past week

PolyPeptide Group AG to Report Fiscal Year 2022 Results on Mar 14, 2023

Investor sentiment deteriorated over the past week

First half 2022 earnings: EPS and revenues miss analyst expectations

Investor sentiment deteriorated over the past week

Consensus EPS estimates fall by 11%

PolyPeptide Group AG to Report First Half, 2022 Results on Aug 19, 2022

Investor sentiment improved over the past week

Investor sentiment improved over the past week

High number of new and inexperienced directors

PolyPeptide Group AG Appoints Monika Casanova as Chief Human Resources Officer and Member of its Management Committee

PolyPeptide Group AG Approves Cash Distribution for the Year 2021, Payable on May 02, 2022

PolyPeptide Group AG Proposes Cash Distribution for the Year 2021

Investors Shouldn't Be Too Comfortable With PolyPeptide Group's (VTX:PPGN) Robust Earnings

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Investor sentiment deteriorated over the past week

Insufficient new directors

Insufficient new directors

Consensus EPS estimates increase to €1.57

PolyPeptide Group AG has completed an IPO in the amount of CHF 737.39136 million.

Stability and Growth of Payments

Dividend Yield vs Market

Earnings Payout to Shareholders

Cash Payout to Shareholders

Discover strong dividend paying companies